Request Demo
Last update 24 May 2025
WT1-Sensitized Allogeneic T-Lymphocytes(NCI)
Last update 24 May 2025
Overview
Basic Info
Drug Type T-lymphocyte cell therapy |
Synonyms- |
Target- |
Action- |
Mechanism T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with WT1-Sensitized Allogeneic T-Lymphocytes(NCI)NCT01640301
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Patients With Relapsed AML
100 Clinical Results associated with WT1-Sensitized Allogeneic T-Lymphocytes(NCI)
Login to view more data
100 Translational Medicine associated with WT1-Sensitized Allogeneic T-Lymphocytes(NCI)
Login to view more data
100 Patents (Medical) associated with WT1-Sensitized Allogeneic T-Lymphocytes(NCI)
Login to view more data
100 Deals associated with WT1-Sensitized Allogeneic T-Lymphocytes(NCI)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic phase chronic myeloid leukemia | Phase 2 | United States | 06 Dec 2012 | |
| Hematopoietic stem cell transplantation | Phase 2 | United States | 06 Dec 2012 | |
| Myelodysplastic Syndromes | Phase 2 | United States | 06 Dec 2012 | |
| Relapsing acute myeloid leukemia | Phase 2 | United States | 06 Dec 2012 | |
| Treatment related acute myeloid leukaemia | Phase 2 | United States | 06 Dec 2012 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 47 | (Arm I (High-risk for Relapse After HCT)) | xkutdemiqd = auxatkannu aegdrblxvp (eqlrpwvjeo, getxshybiu - pxldppkslu) View more | - | 23 Jun 2022 | ||
Laboratory Biomarker Analysis+WT1-Sensitized Allogeneic T-Lymphocytes+Fludarabine Phosphate+Cyclophosphamide+Aldesleukin (Arm II (Relapsed After HCT)) | xkutdemiqd = qupudkczow aegdrblxvp (eqlrpwvjeo, dtdeosgndr - jittfgufyb) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free